Giant urticaria and persistent neutralizing antibodies after the first natalizumab infusion

Neurology

Volumn 74, Issue 17, 2010, Pages 1394-1395

  Cohen, M ^a   Rocher, F ^b   Vivinus, S ^c   Thomas, P ^a   Lebrun, C ^a  

^a Service de Neurologie   (France)

^b PASTEUR HOSPITAL   (France)

^c Centre de Allergologist   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; NATALIZUMAB; PREDNISONE;

ABDOMINAL PAIN; ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEVER; HUMAN; HYPERSENSITIVITY REACTION; LARYNX EDEMA; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

EID: 77951751555     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181dad567     Document Type: Article

References (7)

1. Polman CH, O'Connor PW, Havrdova E, et al, AFFIRM investigators. A randomised, placebo-controlled trial of na-talizumab for relapsing-remitting multiple sclerosis. N Engl J Med 2006;354:899-910.
2. Phillips JT, O'Connor PW, Havrdova E, et al. Infusion-related hypersensitivity reactions during natalizumab treatment [erratum 2007;68:473]. Neurology 2006;67: 1717-1718. (Pubitemid 44747962)
3. Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007; 69:1391-1403. (Pubitemid 47511460)
4. Leussink VI, Lehmann HC, Hartung HP, Gold R, Kie-seier BC. Type III systemic allergic reaction to natalizumab. Arch Neurol 2008;65:851-852. (Pubitemid 351831477)
5. Hellwig K, Schimrigk S, Fischer M, et al. Allergic and nonallergic delayed infusion reactions during natalizumab therapy. Arch Neurol 2008;65:656-658. (Pubitemid 351679662)
6. Krumbholz M, Pellkofer H, Gold R, Hoffmann LA. Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol 2007; 64:1131-1133. (Pubitemid 47403090)
7. Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-o:-1,3-galactose. N Engl J Med 2008;358:1109-1117. (Pubitemid 351398485)